Efficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia – A multicentric clinical trial
Indian Journal of Ophthalmology · 2025-09 · 73 (9) · 1251-1257
DOI: 10.4103/ijo.ijo_680_25 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 29.08.2025. Verfasst von Parul Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology (DOP), GSVM Hospital, Kanpur, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Pilocarpine, Visual Acuity, Presbyopia, Vision, Binocular. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the efficacy and safety of 1.25% pilocarpine compared to placebo for the treatment of presbyopia.
Methods
This multicenter, randomized, double-masked clinical trial compared pilocarpine 1.25% to placebo in presbyopic individuals aged 45–55 years, meeting standard near vision impairment criteria. Participants were randomized 1:1 using a computer-generated sequence, with identical, unmarked bottles ensuring masking. Distance-corrected near visual acuity (DCNVA) and distance-corrected intermediate visual acuity (DCIVA) were assessed under mesopic and photopic conditions across multiple visits (days 1, 3, 7, 14, and 30). The primary outcome was a ≥ 3-line gain in mesopic, high-contrast, binocular DCNVA at day 30, hour 3. Secondary outcomes included photopic and intermediate vision improvements.
Results
A total of 234 participants (mean age 49 ± 3 years, 57% male) were randomized equally. By day 3, pilocarpine demonstrated a significant half-line improvement in high-contrast, binocular mesopic DCNVA (0.47 ± 0.1 vs. 0.51 ± 0.1 logMAR, P = 0.03), progressing to 1.3 lines by day 30 (0.37 ± 0.1 vs. 0.50 ± 0.1, P < 0.001). Nearly 50% achieved a two-line gain (n = 54 [46%] vs. 10 [8%], P = 0.001), and one-third gained three lines (n = 36 [31%)] vs. 5 [4%], P < 0.001). Pilocarpine’s effect was cumulative, with each visit’s baseline DCNVA surpassing prior measurements ( P < 0.001). Photopic DCNVA followed a similar trend (0.31 ± 0.1 vs. 0.43 ± 0.1 logMAR, P = 0.02 at day 30, hour 3). Intermediate DCIVA showed a modest half-line improvement by day 30. No adverse drug reactions or ophthalmic side effects were observed during the study.
Conclusion
Pilocarpine 1.25% effectively improves near vision in presbyopia, with sustained benefits up to day 30 and potential long-term adaptability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology (DOP), GSVM Hospital, Kanpur, Uttar Pradesh, India.
- Department of Ophthalmology (DOP), Anand Multispeciality Hospital and Research Centre, Gandhinagar, Gujarat, India.
- Regulatory Affairs, Entod Pharmaceuticals Ltd, Mumbai, Maharashtra, India.
- Department of Ophthalmology (DOP) Future Vision Eye Care, Mumbai, Maharashtra, India.
- Department of Ophthalmology (DOP), National Institute of Ophthalmology, Pune, Maharashtra, India.
- CEO, Biosite Research Private Limited, Bengaluru, Karnataka, India.
Zitieren
APA
Singh, P., Garasiya, T., Ajila, V., Sengupta, S., Datta, A., & Nivean, M. (2025). Efficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia – A multicentric clinical trial. Indian Journal of Ophthalmology, 73(9), 1251-1257. https://doi.org/10.4103/ijo.ijo_680_25
Vancouver
Singh P, Garasiya T, Ajila V, Sengupta S, Datta A, Nivean M. Efficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia – A multicentric clinical trial. Indian Journal of Ophthalmology. 2025;73(9):1251-1257. doi:10.4103/ijo.ijo_680_25
BibTeX
@article{Singh2025,
author = {Singh, Parul and Garasiya, Tejal and Ajila, Vidya and Sengupta, Sabyasachi and Datta, Aditi and Nivean, M},
title = {Efficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia – A multicentric clinical trial},
journal = {Indian Journal of Ophthalmology},
year = {2025},
volume = {73},
number = {9},
pages = {1251--1257},
doi = {10.4103/ijo.ijo_680_25}
}
EUVIMED